All tagged KRATOM

Eight-Factor Analysis of Kratom: 2022 School of Pharmacy, Concordia University Wisconsin

Eight-Factor Analysis of Kratom: 2022 School of Pharmacy, Concordia University Wisconsin

Admin
science, Eight-Factor Analysis

Based on our review of the available literature, we conclude that regulation of M. speciosa in Wisconsin as a schedule-I substance is not justified at this time. We base this conclusion, in part, on the scientific evidence demonstrating that M. speciosa and its chemical constituents have lower potential for overdose and abuse relative to other agents that are not scheduled in this way. We believe that controlling M. speciosa and its chemical constituents under schedule-I harms public health and stifles much-needed research into its therapeutic and toxic properties.

WHO ECDD PRE-REVIEW OF KRATOM

WHO ECDD PRE-REVIEW OF KRATOM

Admin
science, WHO ECDD

WHO review history Kratom has been under ECDD surveillance since 2020 due to a country level report indicating the potential for abuse, dependence, and harm to public health from mitragynine and 7-hydroxymitragynine, and a report from an international organization regarding documented fatalities associated with kratom use. A pre-review on kratom, mitragynine, and 7-hydroxymitragynine was initiated following consideration of these reports.

Natural Herb Kratom May Have Therapeutic Effects And Relatively Low Potential For Abuse Or Harm, According To A User Survey

Natural Herb Kratom May Have Therapeutic Effects And Relatively Low Potential For Abuse Or Harm, According To A User Survey

Admin
science, survey, Harm Reduction

Researchers say findings underscore need for research and regulation, but not an outright ban on sales

Credit: Johns Hopkins Medicine

Using results of a survey of more than 2,700 self-reported users of the herbal supplement kratom, sold online and in smoke shops around the U.S., Johns Hopkins Medicine researchers conclude that the psychoactive compound somewhat similar to opioids likely has a lower rate of harm than prescription opioids for treating pain, anxiety, depression and addiction.

In a report on the findings, published in the Feb. 3 issue of Drug and Alcohol Dependence, the researchers caution that while self-reporting surveys aren’t always entirely reliable, they confirmed that kratom is not regulated or approved by the U.S. Food and Drug Administration (FDA), and that scientific studies have not been done to formally establish safety and benefits. They say that U.S. drug agencies should seek to study and regulate rather than ban kratom sales outright because of its seemingly safe therapeutic potential, and as a possible alternative to opioid use.